Two juries considering damages against Pfizer for its menopause drug Prempro reached different conclusions, and a judge's decision to keep out disputed evidence may have been the deciding factor.
Evidence rulings prove crucial in Prempro cases
Daily Business Review
June 4, 2012
This article requires free registration
This article requires free registration to Daily Business Review. Please sign in or register to read the full text.